AstraZeneca CEO says "tariffs have limited impact on us"

Currently, European pharmaceutical companies are facing a 15% tariff threat in the US-EU trade agreement. Analysts warn that this tariff rate may hinder the development of European companies and drag down the regional economy. However, AstraZeneca had previously stated in April that if the tariffs imposed by the US on European drugs are in line with those of other industries, they will maintain their sales target for 2025. "The tariff issue has limited impact on us," said the company's CEO Pascal Soriot on Tuesday.